Skip to main content
CVS logo

CVS · CVS HEALTH Corp

Track CVS — free
$83.07 -2.74 (-3.19%)
Market Cap
$109.79B
Shares
1.28B
Volume · Nov 18 4.62M Avg daily vol (3M) 9.11M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$85.81 Open$85.84 Day$84.67–86.89 52W close$70.08–110.60 Avg vol 30d10.9M Short int17.9M · 1.4% of shares · 2.8d Short vol22% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Feb 9, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 4
Earnings call
Split into two publicly traded companies planned for first half of 2028

CVS Health expects its separation into two independent, publicly traded companies to be completed in the first half of 2028, raised 2026 adjusted EPS guidance to at least $8.20 and forecast at least $8.65 for 2027.

4 source passages
Today, we announced our intention to separate into two independent, publicly traded companies. We expect the separation transaction to be tax-free for U.S. federal income tax purposes and to be completed in the first half of 2028, subject to customary conditions, including final board approval, Form 10 effectiveness, and receipt of customary tax confirmation. Building on our continued strong performance so far this year, we are raising our full year 2026 adjusted earnings per share guidance to at least $8.20. Pulling it all together and reflecting the strong performance we saw in the third quarter, we now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Two-company split planned as operating income surges

CVS Health plans to separate into CVS Health and CVS Pharmacy in the first half of 2028; nine-month operating income increased $10.4 billion, or 408.2%, as prior-year charges did not recur.

Revenue $108.4B ▲ 5.4% Net income $2.17B Diluted EPS $1.68
Read from the MD&A section
4 source passages
On November 4, 2026, CVS Health announced its intention to separate into two independent, publicly traded companies in a transaction that is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. The healthcare solutions company, in the interim, will be referred to as CVS Health. The retail pharmacy and community healthcare company will be named CVS Pharmacy. The separation is expected to be completed in the first half of 2028, subject to customary conditions, including, among others, final approval by the CVS Health Board of Directors, effectiveness of a Form 10 registration statement filed with the SEC and receipt of customary confirmation that the separation is expected to be tax-free to CVS Health and its shareholders. Operating income increased $10.4 billion, or 408.2%, in the nine months ended September 30, 2026 compared to the prior year primarily due to the absence of the $5.7 billion goodwill impairment charge and the $1.2 billion in legacy litigation charges, both recorded in the prior year, as well as improved operating performance across all operating segments. Open the document at this passage
Nov 4
Current report 8-K
Plans separation into two publicly traded healthcare companies

CVS Health intends to separate into a healthcare solutions company and CVS Pharmacy in the first half of 2028; David Joyner and Prem Shah will lead the respective companies as CEOs.

Regulation FD disclosure
4 source passages
CVS Health® (NYSE: CVS) today announced that it intends to separate into two independent, publicly traded companies, each committed to innovating to make healthcare more affordable, accessible, and simpler to navigate for the millions of people each serves. Expected to be completed in the first half of 2028 by means of a separation that is intended to be tax-free to CVS Health and its shareholders The pharmacy company, CVS Pharmacy, will continue to serve as the most frequent healthcare touchpoint for communities across the nation. Upon separation, David Joyner, currently Chairman and CEO of CVS Health, will be the Chairman and CEO of the healthcare solutions company, and Prem Shah, currently Group President of CVS Health, will be the CEO of CVS Pharmacy. Open the document at this passage
Nov 4
Current report 8-K
Raises 2026 Guidance as Revenue Grows 5.4%

CVS Health reported third-quarter revenue of $108.4 billion, up 5.4%, and Adjusted EPS of $2.09, while raising full-year 2026 GAAP EPS guidance to at least $6.98, Adjusted EPS to at least $8.20 and cash flow to at least $15.5 billion.

Financial results
7 source passages
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2026. Third quarter total revenues increased to $108.4 billion, up 5.4% year-over-year Adjusted EPS of $2.09 Raising full-year 2026 guidance: GAAP diluted EPS guidance to at least $6.98 from a range of $6.84 to $7.04 Adjusted EPS guidance to at least $8.20 from a range of $7.90 to $8.10 Cash flow from operations guidance to at least $15.5 billion from at least $11.5 billion Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$420.61B
Trailing 12 months
Net income (TTM)
$11.04B
Trailing 12 months
Revenue growth YoY
+5.4%
Year over year
Operating margin
3.6%
Trailing 12 months
P / E (TTM)
10.0
Trailing earnings · reciprocal yield 10.0%
FCF yield
14.2%
TTM · current market cap
Return on invested capital
10.9%
Trailing 12 months
Net cash
−$45.79B
Latest balance sheet
Dividend yield
3.1%
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
+9.4%
Trailing year
Short interest
1.4%
Latest settlement · 2.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. CVS Health reported Q2 2026 adjusted EPS of $2.58 (up ~40% YoY) and revenue of $106.1 billion (up 7.3%), raised full-year 2026 adjusted EPS guidance by $0.60 to $7.90–$8.10 and cash flow from operations guidance to at least $11.5 billion, while flagging 340B and Caremark membership declines as 2027 headwinds.

Bullish
  • + Q2 adjusted EPS rose over 40% YoY to $2.58 with adjusted operating income up 35%
  • + Q2 revenue grew 7.3% to $106.1 billion with growth across all operating segments
  • + Raised full-year 2026 adjusted EPS guidance by $0.60 to $7.90–$8.10
  • + Raised full-year 2026 cash flow from operations guidance to at least $11.5 billion (up $2 billion)
  • + Health Care Benefits adjusted operating income up 85.5% YoY with MBR improving 250 bps to 87.4%
  • + Pharmacy & Consumer Wellness segment delivered over 10% adjusted operating income growth with same-store pharmacy sales up ~3% and prescription volume up 7%
Bearish
  • − 340B program dynamics flagged as a headwind for 2027
  • − Caremark expected to see membership declines in 2027 due to selling season dynamics and health plan product actions
  • − Medical membership declined ~700K YoY to ~26 million, partly due to exit from individual exchange business

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Fair Quant / Vol Moderate
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross Death cross
Price vs 200-day avg −4%
below
Price vs 50-day avg −4%
below
RSI (14) 44
neutral
MACD trend Positive
52-week position 39%
mid-range
Momentum
relative strength
Weak
1-month return −9%
trailing
6-month return −8%
trailing
YTD return +8%
this year
Relative strength −5%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) Death cross
50d $89 › 200d $89 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +134 funds added
Insider flow Accumulating
Net +$2.0M over 90 days · 0% sells
Short interest Rising
1.40% of shares out · ▲ +10.4% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,998 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Fair
Revenue growth +8%
Y/Y
Gross margin 7%
contracting
EPS growth −62%
Y/Y
Free cash flow $7.8B
Valuation P/E 10
below peers
Buyback $10.0B
remaining
Balance sheet $56.1B
net debt
Quant / Vol
risk profile
Moderate
Volatility 34%
annualized · 1-yr
Max drawdown −28%
past year
ATR 3.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 6
Latest guidance · from the 8-K filed Nov 4, 2026
Year Ending December 31, 2026
Adjusted EPS at least $8.20
Full-year 2026
Cash flow from operations at least $15.5B
full-year 2026
GAAP diluted EPS at least $6.98
prior FY $1.39 midpoint +402.2% Y/Y
Previous outlook earlier release · from the 8-K filed Feb 10, 2026

Still-open targets the latest release did not restate under the same label.

Cash flow from operations · 2026 Full-Year at least $9B
Net income attributable to CVS Health · Year Ending December 31, 2026 $7,638 – $7,892
Adjusted income attributable to CVS Health · Year Ending December 31, 2026 $8,998 – $9,252
Guided vs delivered · last 6 settled
Total revenues full year 2025
guided at least $397B
$402.07B In line
GAAP diluted EPS full-year 2025
guided $3.84 – $3.94
$1.39 Miss −64.3%
GAAP diluted EPS full-year 2024
guided $4.95 – $5.20
$3.66 Miss −27.9%
GAAP diluted EPS full-year 2023
guided $6.37 – $6.61
$6.47 In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
−4% Neutral
RSI (14)
44 Neutral
MACD trend
Positive Bullish
52-week position
39% Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) Death cross
50d $89 › 200d $89 — 200d above 50d
Institutional flow Distributing
-5% holders QoQ · +134 funds added
Insider flow Accumulating
Net +$2.0M over 90 days · 0% sells
Short interest Rising
1.40% of shares out · ▲ +10.4% MoM · 2.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,998 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $70 Now $86 · 39% Range high $111
vs 200-day avg -4% vs 50-day avg -4% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EPS non-GAAP $5.16 Six Months Ended June 30 —
Adjusted income attributable to CVS Health non-GAAP 6.62B Six Months Ended June 30, 2026 —
Adjusted operating income non-GAAP 10.31B Six Months Ended June 30 —
Adjusted operating income (loss) - Corporate/Other non-GAAP -1.05B Six Months Ended June 30, 2026 —
Adjusted operating loss non-GAAP -$477M Three Months Ended June 30, 2026 filing —
Days claims payable 41.7 As of June 30, 2026 —
Health Care Benefits Adjusted operating income non-GAAP 5.47B Six Months Ended June 30 —
Health Services Adjusted operating income non-GAAP 3.22B Six Months Ended June 30 —
Medical benefit ratio ("MBR") 86% Six Months Ended June 30 —
Medical membership 26M As of June 30, 2026 —
Medicare Prescription Drug Plan (stand-alone) 3.87M June 30, 2026 —
People served through health insurance products and related services 37M As of June 30, 2026 —
Pharmacy & Consumer Wellness Adjusted operating income non-GAAP 2.67B Six Months Ended June 30 —
Pharmacy claims processed 937.7M Six Months Ended June 30 —
Plan members 87M As of June 30, 2026 —
Prescriptions filled 908.2M Six Months Ended June 30 —
Retail pharmacy locations 9,000 As of June 30, 2026 —
Same store sales increase: Front Store 1% Q4 —
Same store sales increase: Pharmacy 2.9% Q4 —
Total medical membership 26.02M June 30, 2026 —
Walk-in and primary care medical clinics 1,000 As of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Healthcare Plans — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CVS
CVS HEALTH Corp
this stock
$109.79B +8.1% +7.8% 10.0 1.4%
UNH
Unitedhealth Group Inc
$349.16B +18.0% +11.8% 22.3 1.6%
ELV
Elevance Health, Inc.
$93.75B +23.8% +12.5% 18.4 2.1%
CI
Cigna Group
$77.49B +6.8% +11.2% 13.0 2.4%
HUM
Humana Inc
$51.07B +73.1% +10.1% 41.3 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,998
% held
86.7%
Net QoQ
-29.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
1,230
View
Short & Settlement
Short Interest Rising
Shares short
17.9M
Days to cover
2.8d
Change
+1.7M sh
View
Short Volume
Short vol %
22%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
27
Value
$2.5K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
46.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$2.0M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$402.1B
Net income (FY)
$1.8B
EPS diluted
$1.39
View
Buybacks
Authorized · 2 programs
$20.0B
Remaining
$10.0B
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 9, 2026
This year
20
View
Proposed Sales
Value
$214.3K
Shares
2.3K
Filed
May 22, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
CVS Health study highlights GLP-1…
Published
Nov 15, 2026
View

Performance

5D 20D 120D MTD YTD
CVS -3.6% -9.4% -7.7% -4.9% +8.1%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -1.3% -4.7% -4.8% -1.8% +0.7%

Capital returns

Latest dividend
$0.665 / share · ex Oct 22, 2026
Raised 9.9%
Paid (TTM)
$2.66 / share · 4 payouts
Dividend yield (TTM, derived)
3.10%
Full dividend history
Buyback programs · 2 active · as of Sep 30, 2026
Authorized (total)
$20.00B
Spent (derived)
$10.00B
Remaining
$10.00B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 64803 CUSIP 126650100 13F (30d) 1823 filings 1708 filers Visit website Investor relations